Anxiolytics targeting GABAA receptors: Insights on etifoxine - PubMed (original) (raw)
Review
Anxiolytics targeting GABAA receptors: Insights on etifoxine
Pierrick Poisbeau et al. World J Biol Psychiatry. 2018.
Abstract
Objectives: Anxiety and adjustment disorders are among the most prevalent mental health conditions. This review focuses on γ-aminobutyric acid receptor type A (GABAAR)-mediated anxiolysis, describing the action of both endogenous and exogenous modulators of GABAAR. Future directions and innovative strategies to alleviate anxiety symptoms are discussed, with a particular emphasis on etifoxine.
Methods: We used available data from the recent literature to update the mode of action of anxiolytics. We focussed our search on anxiolytics acting at GABAARs, as well as on the pharmacological properties of formerly and currently prescribed anxiolytics.
Results: Considering the adverse effects of current treatments aimed at increasing inhibitory controls, optimisation of existing pharmacotherapies is of crucial importance. Among the alternative compounds targeting the GABAergic system, translocator protein (TSPO) ligands, such as etifoxine (EFX), which promote endogenous neurosteroidogenesis, are emerging as promising candidates for anxiety relief. In several papers comparing the efficacy of benzodiazepines and EFX, EFX showed interesting properties with limited side effects. Indeed, neurosteroids are potent GABAAR modulators with highly underrated anxiolytic properties.
Conclusions: Novel therapeutic strategies have been emerging following the recognition of neurosteroids as potent anxiolytics. Featured at the top of the list for well-tolerated anxiety relief, TSPO ligands such as etifoxine appear promising.
Keywords: Anxiety; barbiturates; benzodiazepines; inhibition; neurosteroids.
Similar articles
- Involvement of the GABAA receptor α subunit in the mode of action of etifoxine.
Mattei C, Taly A, Soualah Z, Saulais O, Henrion D, Guérineau NC, Verleye M, Legros C. Mattei C, et al. Pharmacol Res. 2019 Jul;145:104250. doi: 10.1016/j.phrs.2019.04.034. Epub 2019 May 3. Pharmacol Res. 2019. PMID: 31059790 - Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile.
Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R. Nothdurfter C, et al. J Neuroendocrinol. 2012 Jan;24(1):82-92. doi: 10.1111/j.1365-2826.2011.02166.x. J Neuroendocrinol. 2012. PMID: 21609361 Review. - Translocator protein ligands as promising therapeutic tools for anxiety disorders.
Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C. Taliani S, et al. Curr Med Chem. 2009;16(26):3359-80. doi: 10.2174/092986709789057653. Epub 2009 Sep 1. Curr Med Chem. 2009. PMID: 19548867 Review. - Dissociation of endocrine responses to the Trier Social Stress Test in Virtual Reality (VR-TSST) by the benzodiazepine alprazolam and the translocator protein 18 kDa (TSPO) ligand etifoxine.
Bahr LM, Maurer F, Weigl J, Weber K, Melchner D, Dörfelt A, Wechsler TF, Bauer O, Reinders J, Milenkovic VM, Wetzel CH, Wetter TC, Rupprecht R, Mühlberger A, Nothdurfter C. Bahr LM, et al. Psychoneuroendocrinology. 2021 Feb;124:105100. doi: 10.1016/j.psyneuen.2020.105100. Epub 2020 Dec 5. Psychoneuroendocrinology. 2021. PMID: 33338971 Clinical Trial. - Translocator protein as a promising target for novel anxiolytics.
Costa B, Da Pozzo E, Martini C. Costa B, et al. Curr Top Med Chem. 2012;12(4):270-85. doi: 10.2174/156802612799078720. Curr Top Med Chem. 2012. PMID: 22204481 Review.
Cited by
- Local and global effects of sedation in resting-state fMRI: a randomized, placebo-controlled comparison between etifoxine and alprazolam.
Wein S, Riebel M, Seidel P, Brunner LM, Wagner V, Nothdurfter C, Rupprecht R, Schwarzbach JV. Wein S, et al. Neuropsychopharmacology. 2024 Oct;49(11):1738-1748. doi: 10.1038/s41386-024-01884-5. Epub 2024 May 31. Neuropsychopharmacology. 2024. PMID: 38822128 Free PMC article. Clinical Trial. - Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD).
Iffland M, Livingstone N, Jorgensen M, Hazell P, Gillies D. Iffland M, et al. Cochrane Database Syst Rev. 2023 Oct 9;10(10):CD011769. doi: 10.1002/14651858.CD011769.pub2. Cochrane Database Syst Rev. 2023. PMID: 37811711 Review. - Bibliometric Analysis on GABA-A Receptors Research Based on CiteSpace and VOSviewer.
Yu X, Gao Z, Gao M, Qiao M. Yu X, et al. J Pain Res. 2023 Jun 19;16:2101-2114. doi: 10.2147/JPR.S409380. eCollection 2023. J Pain Res. 2023. PMID: 37361426 Free PMC article. - Palladium-catalyzed synthesis of 4-sila-4_H_-benzo[d][1,3]oxazines by intramolecular Hiyama coupling.
Lee D, Shintani R. Lee D, et al. Chem Sci. 2023 Mar 22;14(15):4114-4119. doi: 10.1039/d2sc06425a. eCollection 2023 Apr 12. Chem Sci. 2023. PMID: 37063809 Free PMC article. - Long-Term Management of Generalised Anxiety Disorder with Low-Dose Continuous Infusions of Flumazenil: A Case Series.
Gallo AT, Addis S, Martyn V, Ramanathan H, Wilkerson GK, Hood SD, Stampfer H, Hulse GK. Gallo AT, et al. Behav Sci (Basel). 2022 Nov 2;12(11):430. doi: 10.3390/bs12110430. Behav Sci (Basel). 2022. PMID: 36354407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical